After moving 0.6% during today's afternoon session, Seagen is now trading at a price of $208.35 per share. On average, analysts give it a target price of $224.83.
Seagen Inc., a biotechnology company, develops and commercializes therapies for the treatment of cancer in the United States and internationally.
Potential Seagen Investors Should Analyze the Following:
-
Seagen has moved 47.0% over the last year.
-
The company has a price to earnings growth (PEG) ratio of 0.6. A number between 0 and 1 could mean that the market is undervaluing Seagen's estimated growth potential
-
Its Price to Book (P/B) ratio is 14.93
Understanding Seagen's Operating Margins
| Date Reported | Total Revenue ($ k) | Operating Expenses ($ k) | Operating Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023-02-15 | 1,962,412 | -2,165,324 | -31 | 27.91 |
| 2022-02-09 | 1,574,371 | -1,944,862 | -43 | -259.26 |
| 2021-02-12 | 2,175,536 | -1,360,964 | 27 | 212.5 |
| 2020-02-06 | 916,713 | -1,093,306 | -24 | 40.0 |
| 2019-02-07 | 654,700 | -826,405 | -40 | 2.44 |
| 2018-02-15 | 482,250 | -623,933 | -41 |
Averaging out to -25.3% over the last 6 years, Seagen's operating margins also have a high coefficient of variability, which stands at 105.1%. The firm's margins exhibit a relatively stable growth trend of 4.4%.
